AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
We recently compiled a list of the Top 10 Stocks to Buy According to Lee Munder Capital Group. In this article, we are going ...
GlobalData on MSN5d
AbbVie and Xilio to collaborate on antibody-based immunotherapiesAbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...
AbbVie Inc. offers a combination of rock-solid business mix, aggressive growth strategy, and shareholder-friendly capital allocation. The company holds strong positions in rapidly growing markets ...
AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...
Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...
NORTH CHICAGO, Ill., Feb. 13, 2025 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.64 per share. The cash dividend is payable ...
Hosted on MSN4d
AbbVie Just Paid Investors: Here’s How Much They ReceivedAbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.
Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback